The 36-month beta value for QNRX is also noteworthy at 1.75. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for QNRX is 1.12M, and at present, short sellers hold a 61.87% of that float. The average trading volume of QNRX on January 23, 2025 was 1.35M shares.
QNRX) stock’s latest price update
The stock price of Quoin Pharmaceuticals Ltd ADR (NASDAQ: QNRX) has dropped by -25.80 compared to previous close of 0.59. Despite this, the company has seen a fall of -25.20% in its stock price over the last five trading days. globenewswire.com reported 2025-01-23 that ASHBURN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces further clinical evidence of the potential efficacy of QRX003 in Netherton Syndrome.
QNRX’s Market Performance
QNRX’s stock has fallen by -25.20% in the past week, with a monthly drop of -32.36% and a quarterly drop of -49.40%. The volatility ratio for the week is 8.62% while the volatility levels for the last 30 days are 14.42% for Quoin Pharmaceuticals Ltd ADR The simple moving average for the last 20 days is -26.72% for QNRX’s stock, with a simple moving average of -32.81% for the last 200 days.
QNRX Trading at -30.94% from the 50-Day Moving Average
After a stumble in the market that brought QNRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.92% of loss for the given period.
Volatility was left at 14.42%, however, over the last 30 days, the volatility rate increased by 8.62%, as shares sank -22.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.58% lower at present.
During the last 5 trading sessions, QNRX fell by -24.88%, which changed the moving average for the period of 200-days by -45.76% in comparison to the 20-day moving average, which settled at $0.5971. In addition, Quoin Pharmaceuticals Ltd ADR saw -32.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at QNRX starting from Carter Denise P., who purchase 555,556 shares at the price of $0.45 back on Dec 23 ’24. After this action, Carter Denise P. now owns 602,648 shares of Quoin Pharmaceuticals Ltd ADR, valued at $250,000 using the latest closing price.
Myers Michael, the Chief Executive Officer of Quoin Pharmaceuticals Ltd ADR, purchase 555,556 shares at $0.45 during a trade that took place back on Dec 23 ’24, which means that Myers Michael is holding 602,808 shares at $250,000 based on the most recent closing price.
Stock Fundamentals for QNRX
Current profitability levels for the company are sitting at:
- -59.48 for the present operating margin
- 0.51 for the gross margin
The net margin for Quoin Pharmaceuticals Ltd ADR stands at -56.48. The total capital return value is set at -1.16. Equity return is now at value -136.11, with -66.14 for asset returns.
Currently, EBITDA for the company is -9.27 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of -5.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.02.
Conclusion
In summary, Quoin Pharmaceuticals Ltd ADR (QNRX) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
